Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Biostar Pharmaceuticals, Inc. Regains Compliance with NASDAQ's Minimum Bid Price Requirement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/21/2012 | 02:16am CET

Biostar Pharmaceuticals, Inc. Regains Compliance with NASDAQ's Minimum Bid Price Requirement

XIANYANG, China, April 20, 2012/PRNewswire-Asia/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in Chinafor a variety of diseases and conditions, today announced that it has received written notification from the Nasdaq Listing Qualifications department that it has regained compliance with the minimum bid price requirement of $1.00per share for continued listing of its common stock on The NASDAQ Global Market set forth in Nasdaq Listing Rule 5450(a)(1), as its common shares achieved a closing bid price of $1.00or more for 10 consecutive business days prior to the compliance deadline of April 23, 2012and this matter is now closed.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit: http://www.biostarpharmaceuticals.com

Safe Harbor relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company's ability to maintain its ongoing compliance with the Nasdaq continued listing requirements, success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, its ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, its ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2011, and other subsequent filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

For more information contact:




BioStar Pharmaceuticals, Inc. 

The Equity Group, Inc.

Zack Pan, CFO 

Lena Cati

Tel: 405-996-8829 

Tel: 212 836-9611

Email: zpan@aoxing-group.com

Email: lcati@equityny.com

SOURCE Biostar Pharmaceuticals, Inc.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
05:38a IBM AUSTRALIA : Northern Trust and IBM Pioneer Use of Blockchain Technology to Help Transform Private Equity Administration
05:33a MACY : JCPenney closing stores, also offering 'voluntary early retirement'
05:33a FIRSTENERGY : Two units at Bruce Mansfield coal plant to restart early next week
05:33a MEDIA STATEMENT : Fuel Price changes to be effected on 01 March 2017
05:33a MEDIA RELEASE : Earthlife/SAFCEI Litigation
05:32a YunNiao.me secures $100 million in Series D funding - Dummy3
05:27a STEMLINE THERAPEUTICS INC : Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm
05:23a TREET : Financial results of Treet Corporation Limited for quarter ended December 31, 2016
05:20a WAL MART STORES : Former employee files discrimination complaint against Lafayette Walmart
05:20a China names new planning chief, commerce minister before key meeting
Latest news
Advertisement
Hot News 
-5.77%Property website Rightmove generates fewer client leads in 2016
-5.13%Baidu posts bleak fourth quarter, but sees business reshuffle driving 2017 growth
-3.94%VIVENDI : Shares Hit Hard by Fall in Profit -- 2nd Update
-3.32%JUPITER FUND MANAGEMENT : full-year profits hit by rising costs
-2.88%BASF : Profit Boosted by Chemicals Business
Most Read News
08:09p Blake Insomnia Therapeutics Inc. Closes Joint Venture with Sajo Consulting LLC
07:46p Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Egalet Corporation of Class Action Lawsuit and Upcoming Deadline - EGLT
07:09p INTU PROPERTIES : Final Results
06:20pDJCITIGROUP : Confirms Investigations Over 'Princelings' Hiring Practices
08:04p QUALCOMM, INC. : Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Qualcomm Incorporated of Class Action Lawsuit and Upcoming Deadline - QCOM
Most recommended articles
02/23DJVIVENDI : Full-Year Earnings Beat Estimates
08:19p MAX AZRIA : Fashion house BCBG Max Azria prepares for bankruptcy - sources
08:13p ALPHABET : self-driving car unit sues Uber with trade theft charge
07:38p CITIGROUP : Citi says U.S. regulators are investigating its hiring practices
07:16pDJWARREN BUFFETT : Top Global Markets News of the Day